Tecvayli Monotherapy Demonstrates Superior Progression-Free and Overall Survival Versus Standard of Care as Early as First Relapse in Patients With Multiple Myeloma Predominantly Refractory to Anti-CD38 Therapy and Lenalidomide
January 15, 2026
January 15, 2026
RARITAN, New Jersey, Jan. 15 -- Johnson and Johnson Innovative Medicine issued the following news release on Jan. 14, 2026:
* * *
TECVAYLI(R) monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
TECVAYLI(R) alone reduced risk of disease progression or death by 71% in a high unmet need populatio . . .
* * *
TECVAYLI(R) monotherapy demonstrates superior progression-free and overall survival versus standard of care as early as first relapse in patients with multiple myeloma predominantly refractory to anti-CD38 therapy and lenalidomide
TECVAYLI(R) alone reduced risk of disease progression or death by 71% in a high unmet need populatio . . .